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Background: This document provides clinical recommendations
for the pharmacologic treatment of chronic obstructive pulmonary
disease (COPD). It represents a collaborative effort on the part of a
panel of expert COPD clinicians and researchers alongwith a team of
methodologists under the guidance of the American Thoracic
Society.
Methods: Comprehensive evidence syntheses were performed on
all relevant studies that addressed the clinical questions and
critical patient-centered outcomes agreed upon by the panel of
experts. The evidence was appraised, rated, and graded, and
recommendations were formulated using the Grading of
Recommendations, Assessment, Development, and Evaluation
approach.
Results: After weighing the quality of evidence and balancing the
desirable and undesirable effects, the guideline panel made the
following recommendations: 1) a strong recommendation for the use
of long-actingb2-agonist (LABA)/long-actingmuscarinic antagonist
(LAMA) combination therapy over LABA or LAMA monotherapy
in patients with COPD and dyspnea or exercise intolerance; 2) a
conditional recommendation for the use of triple therapy with
inhaled corticosteroids (ICS)/LABA/LAMA over dual therapy with
LABA/LAMA in patients with COPD and dyspnea or exercise
intolerance who have experienced one or more exacerbations in the
past year; 3) a conditional recommendation for ICS withdrawal for
patients with COPD receiving triple therapy (ICS/LABA/LAMA)
if the patient has had no exacerbations in the past year; 4) no
recommendation for or against ICS as an additive therapy to long-
acting bronchodilators in patients with COPD and blood
eosinophilia, except for those patients with a history of one or more
exacerbations in the past year requiring antibiotics or oral steroids or
hospitalization, for whom ICS is conditionally recommended as an
additive therapy; 5) a conditional recommendation against the use of
maintenance oral corticosteroids in patients with COPD and a
history of severe and frequent exacerbations; and 6) a conditional
recommendation for opioid-based therapy in patients with COPD
who experience advanced refractory dyspnea despite otherwise
optimal therapy.
Conclusions: The task force made recommendations regarding
the pharmacologic treatment of COPD based on currently
available evidence. Additional research in populations that are
underrepresented in clinical trials is needed, including studies in
patients with COPD 80 years of age and older, those with multiple
chronic health conditions, and thosewith a codiagnosis ofCOPDand
asthma.
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Question 1: In Patients with




Effective than and as Safe as
LABA or LAMA Monotherapy?
Question 2: In Patients with COPD
Who Complain of Dyspnea or
Exercise Intolerance despite the
Use of Dual Therapy with
LABA/LAMA, Is Triple Therapy
with ICS/LABA/LAMA More
Effective than and as Safe as
Dual Therapy with LABA/LAMA?
Question 3: In Patients with COPD
Who Are Receiving Triple
Therapy (ICS/LABA/LAMA),
Should the ICS Be Withdrawn?
Question 4: In Patients with COPD
and Blood Eosinophilia, Should
Treatment Include an ICS in
Addition to a Long-Acting
Bronchodilator?
Question 5: In Patients with COPD
Who Have a History of Severe
and Frequent Exacerbations
despite Otherwise Optimal
Therapy, Is Maintenance Oral
Steroid Therapy More Effective
than and as Safe as No
Maintenance Oral Steroid
Therapy?
Question 6: In Patients with COPD
Who Experience Advanced
Refractory Dyspnea despite
Otherwise Optimal Therapy, Is
Opioid-based Therapy More





In patients with chronic obstructive
pulmonary disease (COPD) who
complain of dyspnea or exercise
intolerance, we recommend long-acting
b2-agonist (LABA)/long-acting
muscarinic antagonist (LAMA)
combination therapy over LABA
or LAMA monotherapy (strong
recommendation, moderate certainty
evidence).
In patients with COPD who
complain of dyspnea or exercise
intolerance despite dual therapy with
LABA/LAMA, we suggest the use of triple
therapy with inhaled corticosteroids
(ICS)/LABA/LAMA over dual therapy
with LABA/LAMA in those patients with
a history of one or more exacerbations in
the past year requiring antibiotics or oral
steroids or hospitalization (conditional
recommendation, moderate certainty
evidence).
In patients with COPD who are
receiving triple therapy
(ICS/LABA/LAMA), we suggest that the
ICS can be withdrawn if the patient has
had no exacerbations in the past year
(conditional recommendation, moderate
certainty evidence).
We do not make a recommendation
for or against ICS as an additive therapy
to long-acting bronchodilators in patients
with COPD and blood eosinophilia,
except for those patients with a history of
one or more exacerbations in the past
year requiring antibiotics or oral steroids
or hospitalization, for whom we suggest
ICS as an additive therapy (conditional
recommendation, moderate certainty
evidence).
In patients with COPD and a
history of severe and frequent
exacerbations despite otherwise optimal
therapy, we advise against the use of
maintenance oral corticosteroid therapy
(conditional recommendation, low
certainty evidence).
In individuals with COPD who
experience advanced refractory dyspnea
despite otherwise optimal therapy, we
suggest that opioid-based therapy be
considered for dyspnea management,
within a personalized shared decision-
making approach (conditional
recommendation, very low certainty
evidence).
Introduction
The Global Initiative for Chronic
Obstructive Lung Disease 2019 report
defines COPD as a “common, preventable
and treatable disease that is characterized
by persistent respiratory symptoms and
airflow limitation that is due to airway or
alveolar abnormalities, usually caused by
significant exposure to noxious particles or
gases” (1). Pharmacologic treatment for
COPD aims to improve quality of life
(QOL) and control symptoms while
reducing the frequency of exacerbations.
The purpose of this clinical practice
guideline is to address specific clinically
important questions regarding the
pharmacologic management of COPD. The
expert panel, in collaboration with a team of
methodologists, prioritized and developed
six questions that addressed significant
COPD management issues. These questions
were rephrased by the methods team using
the Population, Intervention, Comparator,
and Outcomes (PICO) format, and panel
members then compiled and prioritized a
list of outcomes that were important for
clinical decision-making and particularly
important to patients (2, 3). Evidence
syntheses for each PICO question were
focused on clinical outcomes deemed
“critical” for clinical decision-making. The
panel used the Grading of
Recommendations Assessment,
Development, and Evaluation (GRADE)
approach (see Table 1) (2, 3) for the
following clinical questions:
1. In patients with COPD who complain of
dyspnea or exercise intolerance, is
LABA/LAMA combination therapy
more effective than and as safe as LABA
or LAMA monotherapy?
2. In patients with COPD who complain of
dyspnea or exercise intolerance despite
use of dual therapy with LABA/LAMA,
is triple therapy with ICS/LABA/LAMA
more effective than and as safe as dual
therapy with LABA/LAMA?
3. In patients with COPD who are receiving
triple therapy (ICS/LABA/LAMA)
should the ICS be withdrawn?
4. In patients with COPD with blood
eosinophilia, should treatment include
an ICS in addition to a long-acting
bronchodilator?
AMERICAN THORACIC SOCIETY DOCUMENTS
American Thoracic Society Documents e57
5. In patients with COPD who have a
history of severe and frequent
exacerbations despite otherwise optimal
therapy, is maintenance oral steroid
therapy more effective than and as
safe as no maintenance oral steroid
therapy?
6. In patients with COPD who experience
advanced refractory dyspnea despite
otherwise optimal therapy, is opioid-
based therapy more effective than and as
safe as no additional therapy?
The target audience for this guideline
includes specialists in respiratory
medicine. However, given that COPD is
a common condition, primary care
physicians, internists, other healthcare
professionals, patients, and policymakers
may also find benefit from these
recommendations.
Although the panel used a systematic
approach and the best available evidence to
develop this guideline, it is important to note
that study participants in many clinical trials
may not reflect all populations. Specifically,
patients older than 80 years, those with
multiple chronic conditions, and those with
a codiagnosis of COPD and asthma are
rarely represented in clinical trials. We
recommend that for all clinical management
decisions, the patient and the healthcare
provider should engage in a shared decision-
making process.
Methods
The methodology applied in the
development of this document with regard
to formulating questions, rating the
important outcomes, selecting studies, and
synthesizing, formulating, and grading the
evidence is described in detail in the online
supplement. For all outcomes reporting
standardized mean differences (SMDs), we
used a default threshold of 0.50 for the SMD
point estimate to describe a meaningful
clinically important difference (MCID)
(4). Some important aspects of the
methodology are summarized in the
following subsections.
Group Composition
The Task Force co-chairs (L.N. and S.D.A.)
were selected by the American Thoracic
Society (ATS). They led all aspects of project
management and selected the panelists,
which included 18 clinicians and researchers
with experience in COPD. In addition, there
were three methodologists (P.E.A., M.J.M.,
and E.C.) who identified, collected, and
synthesized the evidence, constructed the
evidence profiles, and ensured that all
methodological requirements were met.
The co-chairs and panelists discussed
the evidence and formulated the
recommendations; the methodologists did
not participate in the development of
recommendations. All panel members were
required to disclose their conflicts of
interest. Both co-chairs and at least 50% of
the panel were required to be free from
conflicts of interest. Individuals with
potential conflicts of interest took part in
the evidence discussions but did not
participate in the formulation of
recommendations.
Literature Searches
The literature searches queried MEDLINE,
Embase, and the Cochrane Library (the
Cochrane Central Register of Controlled
Trials and the Cochrane Database of
Systematic Reviews) from 1990 to January
2019. Additional relevant publications that
were found in reference lists, were not
retrieved in the original searching strategy,
or were deemed eligible by the panel, and
more recent studies published between
January and July 4, 2019, were subsequently
screened for eligibility by the methods team
and included in the assessed body of
evidence. All study design types were
included in the searches except for case
report/case series, letters/editorials/narrative
reviews, and abstracts. Thus, the search
included both nonrandomized studies
of interventions and randomized
controlled trials (RCTs). The searches
focused on studies that were conducted in
humans and published in the English
language.
Table 1. Implications of Strong and Conditional Recommendations: From the Grading of Recommendations, Assessment,
Development, and Evaluation Working Group
Strong Recommendation (“We recommend . . .”) Conditional Recommendation (“We suggest . . .”)
For patients The overwhelming majority of individuals in this situation
would want the recommended course of action, and
only a small minority would not. (It is the right course of
action for .95% of patients.)
The majority of individuals in this situation would want the
suggested course of action, but a sizable minority
would not. (It is the right course of action for .50% of
patients.)
For clinicians The overwhelming majority of individuals should receive
the recommended course of action. Adherence to this
recommendation according to the guideline could be
used as a quality criterion or performance indicator.
Formal decision aids are not likely to be needed to help
individuals make decisions consistent with their values
and preferences. (It is reasonable to recommend it
strongly to patients and caregivers.)
Different choices will be appropriate for different patients,
and the clinician must help each patient arrive at a
management decision consistent with her or his values
and preferences. Decision aids may be useful to help
individuals make decisions consistent with their values
and preferences. Clinicians should expect to spend
more time with patients when working toward a
decision. (Slow down, think about it, discuss it with the
patient.)
For policy makers The recommendation can be adopted as policy in most
situations, including for use as a performance indicator.
(The recommended course of action may be an
appropriate performance measure.)
Policy making will require substantial debates and
involvement of many stakeholders. Policies are also
more likely to vary between regions. Performance
indicators would have to focus on the fact that
adequate deliberation about the management options
has taken place. (The recommended course of action is
not appropriate for a performance measure.)
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Manuscript Preparation
The initial draft of the manuscript
was prepared by the co-chairs and
methodologists. The methodologists wrote
the content for the online supplement,
which was edited by the co-chairs. Both
the manuscript and the online supplement
were reviewed, edited, and approved by all
panelmembers before submission. A summary
of the recommendations can be found in
Table 2.
Funding and Updating
Guideline development was funded by
the ATS. The guideline will be reevaluated
in 4–5 years by the relevant ATS Assembly
to determine whether updating is warranted.
Results
Question 1: In Patients with COPD
Who Complain of Dyspnea or
Exercise Intolerance, Is LABA/LAMA
Combination Therapy More Effective
than and as Safe as LABA or LAMA
Monotherapy?
Recommendation. For patients with COPD
who complain of dyspnea or exercise
intolerance, we recommend LABA/LAMA




prioritization by the panel resulted in ranking
hospital admissions, dyspnea, exacerbations,
health-related QOL, and treatment-related
adverse events as critical outcomes.
Summary of the evidence. The expert
medical librarian initially identified 2,543
citations in MEDLINE (n= 1,086), Embase
(n= 1,290), and the Cochrane Library
(n= 167), with deduplication resulting in
n= 1,845 warranting screening. Six
additional studies were identified through
other means. The majority (98.6%) were
ineligible either because of a nonrigorous
study methodology or lack of relevance to
the PICO question, and this resulted in
screeners identifying 24 studies for final
review inclusion. All 24 identified studies
were RCTs (5–28).






1. In patients with COPD who complain
of dyspnea or exercise intolerance, is
LABA/LAMA combination therapy
more effective than and as safe as
LABA or LAMA monotherapy?
In patients with COPD who complain of dyspnea or
exercise intolerance, we recommend LABA/LAMA




2. In patients with COPD who complain
of dyspnea or exercise intolerance
despite the use of dual therapy with
LABA/LAMA, is triple therapy with
ICS/LABA/LAMA more effective than
and as safe as dual therapy with
LABA/LAMA?
In patients with COPD who complain of dyspnea or
exercise intolerance despite dual therapy with
LABA/LAMA, we suggest the use of triple therapy
with ICS/LABA/LAMA over dual therapy with
LABA/LAMA in those patients with a history of one
or more exacerbations in the past year requiring
antibiotics or oral steroids or hospitalization.
Conditional Moderate
certainty
3. In patients with COPD who are
receiving triple therapy
(ICS/LABA/LAMA), should the ICS be
withdrawn?
In patients with COPD who are receiving triple therapy
(ICS/LABA/LAMA), we suggest that the ICS can be




4. In patients with COPD and blood
eosinophilia, should treatment
include an ICS in addition to a long-
acting bronchodilator?
We do not make a recommendation for or against
ICS as an additive therapy to long-acting
bronchodilators in patients with COPD and blood
eosinophilia, except for those patients with a history
of one or more exacerbations in the past year
requiring antibiotics or oral steroids or hospitalization,
for whom we suggest ICS as an additive therapy.
Conditional Moderate
certainty
5. In patients with COPD who have a
history of severe and frequent
exacerbations despite otherwise
optimal therapy, is maintenance oral
steroid therapy more effective than
and as safe as no maintenance oral
steroid therapy?
In patients with COPD and a history of severe and
frequent exacerbations despite otherwise optimal
therapy, we advise against the use of maintenance
oral corticosteroid therapy.
Conditional Low certainty
6. In patients with COPD who
experience advanced refractory
dyspnea despite otherwise optimal
therapy, is opioid-based therapy
more effective than and as safe as no
additional therapy?
In individuals with COPD who experience advanced
refractory dyspnea despite otherwise optimal therapy,
we suggest that opioid-based therapy be considered
for dyspnea management, within a personalized
shared decision-making approach.
Conditional Very low certainty
Definition of abbreviations: COPD=chronic obstructive pulmonary disease; ICS= inhaled corticosteroids; LABA= long-acting b2-agonist;
LAMA= long-acting muscarinic antagonist; PICO=Population, Intervention, Comparator, and Outcomes.
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The total sample size for the 24 studies
was 45,441 participants; 29,589 (65.4%) of
these participants were randomized to the
treatment/intervention arms and 15,852
(34.6%) were in the control (comparator)
arms.
Dyspnea score: assessed using the
Transition Dyspnea Index or COPD
Assessment Test. Eleven studies (n= 17,650)
assessed dyspnea (5, 6, 10, 15, 17, 19, 20, 22,
25–27). Because the Transition Dyspnea
Index (TDI) and the COPD Assessment
Test (CAT) are scored in opposite
directions, changes in CAT values were
multiplied by 21. The panel acknowledged
that the CAT is a broader estimate of health
status; however, one of its core components
is dyspnea. Therefore, the panel believed
that it was reasonable to use this tool as a
proxy for dyspnea when other measures of
dyspnea were unavailable for a particular
study. The studies revealed an increased
score (less breathlessness) in patients
randomized to dual LABA/LAMA therapy
versus monotherapy (SMD=0.10; 95%
confidence interval [CI], 0.07–0.13;
P, 0.001), although this did not reach
the MCID threshold. There was a high
certainty in the estimate of effect based on
GRADE (absolute risk effect was 0.1 SDs
more; 95% CI, 0.07 more to 0.13 more).
Exacerbations. Fifteen studies
(n= 22,733) assessed exacerbation risk (5, 6,
9, 10, 12–14, 17, 19–23, 26, 27). The studies
revealed a reduced risk with dual
LABA/LAMA therapy versus monotherapy
(risk ratio [RR], 0.80; 95% CI, 0.69–0.92;
P= 0.002). There was moderate certainty
in estimates of effect based on GRADE
(absolute risk effect was 88 fewer per
1,000 patients; 95% CI, 136 fewer to 35
fewer).
Health-related QOL: assessed using
the Chronic Respiratory Disease
Questionnaire or St. George’s Respiratory
Questionnaire. Eleven studies (n= 18,897)
assessed health-related QOL (5, 10, 11,
14–18, 22, 24, 25). The studies revealed a
reduced score (improved QOL) favoring
dual LABA/LAMA therapy over
monotherapy (SMD=20.13; 95% CI,
20.16 to 20.10; P, 0.001), although this
did not reach the MCID threshold. There
was high certainty in estimates of effect
based on GRADE (absolute difference was
0.13 SDs fewer; 95% CI, 0.16 fewer to 0.10
fewer).
Hospital admissions. Three studies
(n= 9,719) assessed risk of hospital
admission (10, 19, 26). The studies revealed
a reduced risk with dual LABA/LAMA
therapy versus monotherapy (RR, 0.89;
95% CI, 0.82–0.97; P= 0.01) There was
high certainty in estimates of effect based
on GRADE (absolute risk effect was 19
fewer hospital admissions per 1,000
patients treated with LABA/LAMA as
opposed to monotherapy; 95% CI, 32
fewer to 5 fewer).
Treatment-related adverse
events. Twenty-three studies (n= 38,758)
assessed treatment-related adverse events
(5–17, 19–28). The studies revealed no
significant difference in risk of treatment-
related adverse events with dual
LABA/LAMA therapy versus monotherapy
(RR, 0.99; 95% CI, 0.97–1.01; P= 0.34).
There was high certainty in estimates of
effect based on GRADE (absolute risk effect
was 4 fewer per 1,000 patients; 95% CI, 12
fewer to 4 more).
Summary. Based on the five critical
outcomes and completion of the GRADE
evidence table, the overall certainty of
evidence was judged to be “moderate”
and this certainty was assigned to the
final recommendation as per GRADE
guidance.
Committee discussion. The panel noted
a statistically significant decrease in
exacerbations and hospital admissions
among patients receiving dual therapy as
opposed to monotherapy. The evidence also
showed a statistically significant
improvement in dyspnea and QOL with
dual therapy, although these did not reach
the MCID threshold. In addition, the
available studies did not reveal any
evidence of harm from dual therapy
compared with monotherapy. Given the
above evidence, we believe that patients
would thus opt for dual therapy over
monotherapy.
The panel examined and discussed
feasibility, acceptability, and health-equity
issues, and concluded that dual therapy
would be feasible to implement and would
be acceptable to patients. The panel did note
that dual long-acting bronchodilator
therapy is more expensive than long-acting
bronchodilator monotherapy, and that this
could pose health-equity challenges to
patients of limited means who might be
unable to obtain the drug because of cost or
lack of availability. However, a formal cost-
effectiveness analysis was not performed,
and the literature evidence was not fully
examined in this regard. Because dual long-
acting bronchodilators are available as single
inhalers, the burden of use for patients was
not deemed a factor that would preclude
patients from choosing dual therapy over
monotherapy. However, the panel noted
that if a physician chooses to prescribe two
separate long-acting bronchodilator
inhalers rather than a single combination
dual therapy inhaler, this could increase the
complexity and burden of medication use
for patients.
After considering these issues, and
armed with moderate certainty evidence, the
panel concluded that in patients with COPD
who complain of dyspnea or exercise
intolerance, the balance of benefits of dual
LABA/LAMA therapy outweighs the risks
when compared with LABA or LAMA
monotherapy.
Research needs. The available clinical
trials have demonstrated the superiority
of dual bronchodilator therapy over
single bronchodilator therapy. However,
the panel noted that these trials excluded
certain patient populations, including
patients older than 80 years, those with
multiple chronic conditions, and those with
a codiagnosis of COPD and asthma. Large
sample sizes and high-quality observational
studies with results that reveal large
magnitudes of effect and dose–response
relationships may be useful for
supplementing the available RCT evidence
in these populations.
Question 2: In Patients with COPD
Who Complain of Dyspnea or
Exercise Intolerance despite the Use
of Dual Therapy with LABA/LAMA, Is
Triple Therapy with ICS/LABA/LAMA
More Effective than and as Safe as
Dual Therapy with LABA/LAMA?
Recommendation. In patients with COPD
who complain of dyspnea or exercise
intolerance despite dual therapy with
LABA/LAMA, we suggest the use of triple
therapy with ICS/LABA/LAMA rather than
dual therapy with LABA/LAMA in those
patients with a history of one or more
exacerbations in the past year requiring




prioritization by the panel resulted in
ranking pneumonia, hospital admissions,
exacerbations, ICU admissions, dyspnea,
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and health-related QOL as critical
outcomes.
Subgroup analysis. The panel decided a
priori that a subgroup analysis would be
done based on patients with a history of
one or more COPD exacerbations in the
past year requiring treatment with
antibiotics or oral steroids or
hospitalization versus patients with zero to
less than one exacerbation in the past year
requiring treatment with antibiotics or oral
steroids or hospitalization.
Summary of the evidence. The expert
medical librarian initially identified 1,482
citations in MEDLINE (n= 668), Embase
(n= 768), and the Cochrane Library
(n= 46), with deduplication resulting in
n= 1,102 warranting screening. An
additional two studies were identified
through other means. The majority (99.5%)
were ineligible either because of a
nonrigorous study methodology or lack of
relevance to the PICO question, and this
resulted in screeners identifying four
studies for final review inclusion. The four
identified studies were multicenter RCTs
(19, 29–31). The total sample size for
the four RCTs was 9,313 participants;
5,700 (61.2%) of these participants were
in the treatment/intervention arms and
3,613 (38.8%) were in the control
(comparator) arms. Three of the four
studies enrolled patients with a history
of one or more exacerbations per year
(19, 29, 30). In one study, patients were
not required to have had an exacerbation
in the past year (31).
Pneumonia. Three studies (n= 8,964)
assessed incidence of pneumonia (29–31).
The studies revealed a significantly
increased risk of pneumonia with triple
therapy as compared with dual therapy
(rate ratio, 1.39; 95% CI, 1.02–1.90;
P= 0.03). There was high certainty in
estimates of effect based on GRADE
(absolute risk effect was 15 more
pneumonias per 1,000 patients; 95% CI, 1
more to 35 more). The x2 interaction test
for subgroup differences suggested similar
effects in frequency of pneumonia for those
with a history of one or more exacerbations
in the past year and those with zero to less
than one exacerbation in the past year
(P= 0.74), suggesting that any differences
could be explained by chance.
Hospital admissions. One study
(n= 293) evaluated the risk of all-cause
hospital admissions (19). The study
revealed no significant difference in risk of
hospital admission with triple therapy as
compared with dual therapy (rate ratio,
0.87; 95% CI, 0.62–1.24; P= 0.44). There
was moderate certainty in estimates of
effect based on GRADE (absolute risk effect
was 42 fewer per 1,000 patients; 95% CI,
123 fewer to 78 more). There were no
subgroups available to analyze.
Exacerbations. Four studies (n= 9,257)
evaluated the risk of COPD exacerbations
(19, 29–31). The studies revealed a
significantly decreased risk of exacerbations
with triple therapy as compared with dual
therapy with LABA/LAMA (rate ratio, 0.71;
95% CI, 0.59–0.86; P, 0.001). There was
moderate certainty in estimates of effect
based on GRADE (absolute risk effect was
64 fewer exacerbations per 1,000 patients;
95% CI, 90 fewer to 31 fewer). The x2
interaction test for subgroup differences
suggested different effects in frequency of
exacerbations for those with a history of
one or more exacerbations in the past year
and those with zero to less than one
exacerbation in the past year (P, 0.001).
Subgroup with a history of one or more
exacerbations in the past year. Three studies
(n= 7,993) evaluated the risk of COPD
exacerbations in subjects with a history of
one or more exacerbations in the past
year (19, 29, 30). The studies revealed a
significantly decreased risk of exacerbations
with triple therapy as compared with dual
therapy with LABA/LAMA (rate ratio, 0.77;
95% CI, 0.72–0.81; P, 0. 001). Assuming a
baseline risk of COPD exacerbation in this
subgroup of 1.0 exacerbations per patient
per year, the absolute risk effect was 230
fewer exacerbations per 1,000 patients (95%
CI, 280 fewer to 190 fewer).
Subgroup with zero to less than one
exacerbation in the past year. One study
(n= 1,264) revealed a significant reduction
in the rate of exacerbations with triple
therapy as compared with dual therapy
with LABA/LAMA (rate ratio, 0.48; 95%
CI, 0.37–0.62; P, 0.001) (31). Assuming a
baseline risk of COPD exacerbation in this
subgroup of 0.35 exacerbations per patient
per year, the absolute risk difference/risk
effect was 182 fewer exacerbations per
1,000 patients (95% CI, 220 fewer to 133
fewer).
ICU admissions. ICU admissions were
not reported in any of the RCTs and
therefore could not be analyzed.
Dyspnea score: assessed using the
TDI. Two studies (n= 1,494) assessed
dyspnea (19, 31). The studies revealed no
significant change in dyspnea in patients
treated with triple therapy as compared
with dual therapy (MD=0.20; 95% CI,
20.04 to 0.44; P= 0.11), and this did not
reach the MCID threshold of 1 TDI unit.
There was high certainty in the estimate of
effect based on GRADE (absolute difference
was 0.20 TDI units more; 95% CI, 0.04 less
to 0.44 more). The x2 interaction test for
subgroup differences suggested similar
effects for those with exacerbations and
without exacerbations (P= 0.58), suggesting
that any differences could be explained by
chance.
Health-related QOL: assessed using the
St. George’s Respiratory
Questionnaire. Three studies (n= 6,292)
assessed health-related QOL (19, 30, 31).
The studies revealed a significantly lower
score (improved QOL) favoring triple
therapy over dual therapy (MD=21.56;
95% CI, 22.39 to 20.74; P, 0. 001);
however, this does not exceed the MCID
threshold for a St. George’s Respiratory
Questionnaire (SGRQ) score of 24 units.
There was high certainty in estimates of
effect based on GRADE (absolute difference
was 1.56 SGRQ units less; 95% CI, 2.39
units fewer to 0.74 fewer). The x2
interaction test for subgroup differences
suggested similar effects in health-related
QOL for those with exacerbations and
without exacerbations (P= 0.81), suggesting
that any differences could be explained by
chance.
Summary. Based on the five critical
outcomes and completion of the GRADE
evidence table, the overall certainty of
evidence was judged to be “moderate” and
this certainty was assigned to the final
recommendation as per GRADE guidance.
Committee discussion. The panel
concluded that the benefits of triple therapy
with ICS/LABA/LAMA outweigh the
risks as compared with treatment with
LABA/LAMA dual therapy in patients with
COPD who complain of dyspnea or exercise
intolerance despite dual therapy and have
experienced one or more exacerbations in
the past year. The panel noted that in three
studies that randomized symptomatic
patients with COPD who had a history of
exacerbations, the benefits of triple therapy
in protecting against the risk of future
exacerbations outweighed the increased risk
of pneumonia. In patients with COPD and a
history of one or more exacerbations in the
past year, the 23% rate reduction in
exacerbations was believed to outweigh the
AMERICAN THORACIC SOCIETY DOCUMENTS
American Thoracic Society Documents e61
39% increased rate of pneumonia, as
exacerbation events are much more
common than pneumonia events in these
patients. This was confirmed when the
absolute risk differences were examined.
Patients treated with triple therapy
experienced 15 more pneumonias per 1,000
patients; however, they also experienced 230
fewer COPD exacerbations per 1,000
patients. Thus, the panel concluded that for
patients with COPD and a history of
exacerbations, the benefits of triple therapy
outweigh the risks.
However, the panel concluded that the
benefits of triple therapy do not clearly
outweigh the risks as compared with
treatment with dual therapy in patients with
COPD who have experienced zero to less
than one exacerbation in the past year,
because only one clinical trial that assessed
this specific subgroup was available. In this
study, patients with COPD and no history of
exacerbations had a 39% increased relative
risk of pneumonia and a 52% reduced
relative risk of exacerbations. Patients
treated with triple therapy experienced 15
more pneumonias per 1,000 patients, and
experienced 182 fewer COPD exacerbations
per 1,000 patients. Although the data from
this study suggest that these patients may
benefit from triple therapy, the panel
believed that additional studies are needed
before triple therapy can be recommended
for this subgroup.
The panel examined and discussed
feasibility, acceptability, and health-equity
issues, and concluded that the therapy
options (dual therapy or triple therapy)
would be feasible to implement and would
be acceptable to patients. The panel did note
that triple therapy is more expensive than
dual long-acting bronchodilator therapy,
and that this could pose health-equity
challenges to patients of limited means who
might be unable to obtain the drug because
of cost or lack of availability. However, a
formal cost-effectiveness analysis was not
performed, and the literature evidence was
not fully examined in this regard. Because
triple therapy is available as a single inhaler,
the burden of use for patients was not
deemed a factor that would preclude
patients from choosing triple therapy over
dual therapy. However, the panel noted that
if a physician chooses to prescribe two or
three separate inhalers rather than a single
combination triple therapy inhaler, this
could increase the complexity and burden
of medication use for patients. After
considering these issues, the panel decided
that for patients with COPD who complain
of dyspnea or exercise intolerance, the
balance of benefits of triple therapy with
ICS/LABA/LAMA clearly outweigh the risks
when compared with dual therapy with
LABA/LAMA in those patients with a
history of one or more exacerbations in the
past year requiring antibiotics or oral
steroids or hospitalization.
Research needs. The studies available to
date used the criterion of one or more
exacerbations in the past year to define a
patient with frequent exacerbations. This
criterion is inadequate because there are
likely different risks (and different responses
to pharmacotherapy) for patients depending
on both the number and severity of
exacerbations. For example, a patient with
less than one exacerbation per year would
likely be at low risk, patients with one
exacerbation per year may have a moderate
risk, and patients with two or more
exacerbations per year or those with at least
one severe exacerbation requiring
hospitalization may be at high risk. Trials
using risk stratification of exacerbation risks
to more precisely target a treatment
response are needed. Evidence is also
lacking with regard to the subgroup with no
history of exacerbations, and trials are
needed to better establish the role of triple
therapy in this patient population.
Adequately powered, well-designed
effectiveness studies (e.g., pragmatic
RCTs and nonrandomized studies of
interventions), with larger sample sizes, in
the area of triple therapy versus dual therapy
should be conducted in real-life situations,
such as those involving patients older
than 80 years of age, those with multiple
chronic health conditions, current smokers,
and those with a codiagnosis of COPD
and asthma. The results of such trials
could provide much-needed robust evidence
for optimal personalized clinical
management.
Question 3: In Patients with COPD
Who Are Receiving Triple Therapy
(ICS/LABA/LAMA), Should the ICS Be
Withdrawn?
Recommendation. In patients with COPD
who are receiving triple therapy with
ICS/LABA/LAMA, we suggest that the ICS
can be withdrawn if the patient has had no
exacerbations in the past year (conditional
recommendation, moderate certainty
evidence).
Subgroup analysis. The panel decided a
priori that a subgroup analysis would be
done for the exacerbation outcome based
on patients with a history of one or more
COPD exacerbations in the past year
requiring treatment with antibiotics or oral
steroids or hospitalization versus patients
with no exacerbation in the past year
requiring treatment with antibiotics or oral
steroids or hospitalization.
Critical outcomes. Outcome
prioritization by the panel resulted in
ranking pneumonia, hospital admissions,
exacerbations, all-cause death, ICU
admissions, dyspnea, health-related QOL,
and physical activity as critical outcomes.
Summary of the evidence. The expert
medical librarian initially identified 1,482
citations in MEDLINE (n= 668), Embase
(n= 768), and the Cochrane Library
(n= 46), with deduplication resulting in
n= 1,102 warranting screening. The
majority (99.6%) were ineligible either
because of a nonrigorous study
methodology or lack of relevance to the
PICO question, and this resulted in
screeners identifying three studies for final
review inclusion. The three identified
studies were RCTs; however, one of the
three studies was a subgroup analysis (32)
of a larger trial (33), and thus only two
studies were included for review (33, 34).
The total sample size for the two studies
was 3,538 participants; 1,769 (50%) of
these participants were in the
treatment/intervention arms and 1,769
(50%) were in the control (comparator)
arms. The two studies were both
multicenter trials.
Pneumonia. Two studies (n= 3,538)
assessed incidence of pneumonia (33, 34).
The studies revealed no significant
difference in risk of pneumonia with
withdrawal of ICS and subsequent dual
therapy with LABA/LAMA as compared
with triple therapy (RR, 0.92; 95% CI,
0.67–1.25; P= 0.58). There was moderate
certainty in estimates of effect based on
GRADE (absolute risk effect was 4 fewer
pneumonias per 1,000 patients; 95% CI, 15
fewer to 11 more).
Hospital admissions. One study
(n= 2,485) evaluated the frequency of
hospital admissions (33). The study
revealed no significant difference in
hospital admissions with withdrawal of
ICS and subsequent dual therapy with
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LABA/LAMA as compared with continued
triple therapy (RR, 0.99; 95% CI, 0.86–1.15;
P= 0.93). There was moderate certainty in
estimates of effect based on GRADE
(absolute risk effect was 2 fewer admissions
per 1,000 patients; 95% CI, 31 fewer to 33
more).
Exacerbations. Two studies (n= 3,538)
evaluated the risk of COPD exacerbations
(33, 34). The studies revealed no significant
difference in risk of exacerbations with
withdrawal of ICS and subsequent dual
therapy with LABA/LAMA as compared
with continued triple therapy (rate ratio,
1.07; 95% CI, 0.97–1.17; P= 0.17). There
was moderate certainty in estimates of
effect based on GRADE (absolute effect
was 15 more exacerbation events per
1,000 patients; 95% CI, 7 fewer to 37 more).
The x2 interaction test for subgroup
differences suggested similar effects for the
risk of COPD exacerbations for those with
one or more exacerbations in the past year
and those without a history of
exacerbations (P= 0.88), suggesting that
any differences could be explained by
chance.
All-cause mortality. Two studies
(n= 3,538) evaluated all-cause mortality
(33, 34). The studies revealed no significant
difference in risk of death with withdrawal
of ICS and subsequent dual therapy with
LABA/LAMA as compared with continued
triple therapy (RR, 1.09; 95% CI, 0.73–1.65;
P= 0.66). There was moderate certainty
in estimates of effect based on GRADE
(absolute risk effect was 2 more deaths
per 1,000 patients; 95% CI, 7 fewer to 17
more).
ICU admissions. ICU admissions were
not reported in the RCTs and therefore
could not be analyzed.
Dyspnea. Information regarding
dyspnea was not complete from the
available RCTs, and thus the results could
not be pooled.
Health-related QOL: assessed using the
SGRQ. Two studies (n= 3,538) assessed
health-related QOL (33, 34). The studies
showed a significant decrease in QOL
(increased SGRQ score) with withdrawal
of ICS versus continued triple therapy
(MD= 1.22; 95% CI, 1.15–1.29;
P, 0.0001); however, this does not exceed
the MCID threshold for an SGRQ score of
4 units. There was high certainty in
estimates of effect based on GRADE
(absolute risk effect was 1.22 SGRQ units
higher; 95% CI, 1.15 higher to 1.29 higher).
Physical activity. Physical activity was
not reported in the RCTs and therefore
could not be analyzed.
Summary. Based on the six critical
outcomes and completion of the GRADE
evidence table, the overall certainty of
evidence was judged to be “moderate” and
this certainty was assigned to the final
recommendation as per GRADE guidance.
Committee discussion. According to
the available evidence, withdrawal of ICS
was not associated with a statistically
significant difference in risk of pneumonia,
all-cause mortality, or risk of COPD
exacerbation. The change in QOL did not
exceed the MCID threshold. Given the
paucity of evidence and hence the inability
to confirm the risks and benefits associated
with withdrawal of ICS from triple therapy,
and in light of the analysis of data from
PICO question 2, which showed that triple
therapy is of benefit in patients with a
history of exacerbations, the panel suggests
that ICS can be withdrawn and patients can
be converted from triple therapy to dual
therapy with LABA/LAMA if there is no
history of exacerbations in the past year.
The panel examined and discussed
feasibility, acceptability, and health-equity
issues, and concluded that withdrawal of
ICS from triple therapy would be feasible to
implement, would be acceptable to patients,
and would pose limited (if any) health-
equity challenges. A cost-effectiveness
analysis was not performed, and the
literature evidence was not fully examined in
this regard. However, the panel believed that
the costs of dual therapy versus triple
therapy would not be a rate-limiting step for
patients in terms of access to treatment, as
dual therapy would be expected to be less
expensive than triple therapy. The burden of
use for patients was also not deemed to be a
factor that would preclude them from
choosing dual therapy over triple therapy.
After considering these issues, the panel
concluded that withdrawal of ICS from
triple therapy can be considered for patients
with COPD who do not have a history of
exacerbations in the past year.
Research needs. Adequately powered,
well-designed effectiveness studies in the
area of withdrawal of ICS from triple
therapy are needed to confirm these
findings. These future trials should evaluate
important subgroups, including patients
with different frequencies and severities of
exacerbations, blood eosinophilia, and
asthma/COPD overlap. Evaluation of
additional clinically important outcomes,
such as dyspnea, activity limitation, and
exercise tolerance, may provide further
insight into optimal clinical management.
Question 4: In Patients with COPD
and Blood Eosinophilia, Should
Treatment Include an ICS in Addition
to a Long-Acting Bronchodilator?
Recommendation. We do not make a
recommendation for or against ICS as an
additive therapy to long-acting
bronchodilators in patients with COPD and
blood eosinophilia (defined as >2% blood
eosinophils or >150 cells/ml), except for
those patients with a history of one or more
exacerbations in the past year requiring
antibiotics or oral steroids or
hospitalization, for whom we suggest ICS as




prioritization by the panel resulted in
ranking pneumonia, hospital admissions,
exacerbations, dyspnea, and health-related
QOL as critical outcomes.
Summary of the evidence. The expert
medical librarian initially identified 2,953
citations in MEDLINE (n= 1,734), Embase
(n= 1,187), and the Cochrane Library
(n= 32), with deduplication resulting in
n= 1,923 warranting abstract screening. An
additional seven studies were identified
through other means. The majority (99.4%)
were ineligible either because of a
nonrigorous study methodology or lack of
relevance to the PICO question, and this
resulted in screeners identifying eight
studies for final review inclusion. All eight
identified unique studies were RCTs (29,
31, 35–40). The total sample size for the
eight RCTs was 9,123 participants; 5,945
(65.2%) of these participants were in the
treatment/intervention arms and 3,178
(34.8%) were in the control (comparator)
arms.
The chosen thresholds for the
percentage of eosinophils in blood (>2%
eosinophils) and the number of eosinophils
per microliter of blood (>150) were based
on the values presented in the studies
analyzed for the review.
Pneumonia (>2% eosinophils). Two
studies (n= 4,131) assessed incidence of
pneumonia in patients with >2% blood
eosinophils (35, 38). The studies revealed
an increased risk of pneumonia with an ICS
AMERICAN THORACIC SOCIETY DOCUMENTS
American Thoracic Society Documents e63
in addition to a long-acting bronchodilator
(RR, 1.99; 95% CI, 1.31–3.00; P= 0.001).
There was moderate certainty in estimates
of effect based on GRADE (absolute risk
effect was 26 more pneumonias per 1,000
patients; 95% CI, 8 more to 52 more).
Pneumonia (>150 eosinophils). Two
studies (n= 4,267) assessed incidence of
pneumonia in patients with >150 blood
eosinophils/ml (36, 38). The studies
revealed an increased risk of pneumonia
with an ICS in addition to a long-acting
bronchodilator (RR, 1.55; 95% CI,
1.23–1.95; P, 0.001). There was moderate
certainty in estimates of effect based on
GRADE (absolute risk effect was 44 more
pneumonias per 1,000 patients; 95% CI,
18 more to 76 more).
Hospital admissions. Hospital
admissions were not reported in the studies
and therefore could not be analyzed.
Exacerbations (>2% eosinophils). Six
studies (n= 5,517) assessed rates of COPD
exacerbations in patients with >2% blood
eosinophils (29, 35, 37–40). The studies
revealed a reduced risk of exacerbations
with an ICS in addition to a long-acting
bronchodilator versus a long-acting
bronchodilator (rate ratio, 0.78; 95% CI,
0.67–0.92; P= 0.004). There was moderate
certainty in estimates of effect based on
GRADE. Assuming a baseline risk of
COPD exacerbation in this subgroup of one
exacerbation per patient per year, the
absolute risk effect was 209 fewer
exacerbations per 1,000 patients (95% CI,
313 fewer to 76 fewer).
Exacerbations (>150 eosinophils/ml). Six
studies (n=8,106) assessed rates of COPD
exacerbations in patients with >150 blood
eosinophils/ml (29, 31, 36, 38–40). The
studies revealed a reduced risk of
exacerbations with an ICS in addition to a
long-acting bronchodilator versus a long-
acting bronchodilator (rate ratio, 0.70; 95%
CI, 0.59–0.84; P, 0.001). There was
moderate certainty in estimates of effect
based on GRADE. Assuming a baseline risk
of COPD exacerbation in this subgroup of
one exacerbation per patient per year,
the absolute risk effect was 285 fewer
exacerbations per 1,000 patients (95% CI,
390 fewer to 152 fewer).
Dyspnea score: assessed using the TDI
(>150 eosinophils/ml). One study (n=4,269)
assessed dyspnea in patients with>200 blood
eosinophils/ml (36). The study revealed no
significant difference in dyspnea with an ICS
in addition to a long-acting bronchodilator
versus a long-acting bronchodilator
(MD=0.16; 95% CI, 20.15 to 0.47; P=0.31),
and this did not reach the MCID threshold
for a TDI of 1 unit. There was moderate
certainty in estimates of effect based on
GRADE (absolute difference was 0.16 units
more; 95% CI, 0.15 fewer to 0.47 more).
Health-related QOL: assessed using the
SGRQ (>150 eosinophils/ml). Two studies
assessed health-related QOL (n= 4,762) (36,
39). The studies revealed a statistically
improved QOL with an ICS in addition to a
long-acting bronchodilator versus a long-
acting bronchodilator (MD=22.31 units;
95% CI, 23.83 to 20.78; P= 0.003),
however, this does not exceed the MCID
threshold for an SGRQ score of 24 units.
There was moderate certainty in estimates
of effect based on GRADE (absolute
difference was 2.31 units fewer; 95% CI,
3.83 fewer to 0.78 fewer).
Summary. Based on the five critical
outcomes and completion of the GRADE
evidence table, the overall certainty of
evidence was judged to be “moderate” and
this certainty was assigned to the final
recommendation as per GRADE guidance.
Committee discussion. According to the
available evidence, the addition of ICS to a
long-acting bronchodilator in patients with
COPD and blood eosinophilia was associated
with a significantly increased risk of
pneumonia and a significantly decreased risk
of exacerbations. Patients with blood
eosinophilia treated with ICS plus long-acting
bronchodilators experienced 26–44 more
pneumonias per 1,000 patients, and 209–285
fewer COPD exacerbations per 1,000 patients.
However, the panel recognized that the
studies included within this PICO question
analyzed the effects of ICS and long-acting
bronchodilators in patients with elevated
blood eosinophils as subgroup analyses. In
many cases, the subgroup analyses were
performed post hoc after the primary trial
results had already been published. In
addition, nonstandardized thresholds were
used in the various studies to define
“eosinophilia.” Thus, the panel believed the
quality of the available studies providing
the evidence was not optimal, and hence
the committee was reluctant to recommend
ICS for all patients with COPD and blood
eosinophilia. However, given the weight of
the evidence presented in PICO 2, which
shows that ICS are beneficial in patients
with a history of exacerbations, the panel
concluded that patients with blood
eosinophilia and a history of exacerbations
would likewise benefit from the addition of
ICS to a long-acting bronchodilator.
The panel believed that the addition of
ICS to a long-acting bronchodilator in
patients with blood eosinophilia and a
history of exacerbations is feasible, and the
burden of therapy would be acceptable to
patients. A cost-effectiveness analysis was
not performed because the literature was not
fully examined in this regard. However, the
panel did note that combination inhaled
steroid/long-acting bronchodilator therapy
is more expensive than long-acting
bronchodilator monotherapy, and this
could pose health-equity challenges to
patients of limited means who might be
unable to obtain the drug because of cost or
lack of availability. The burden of use for
patients was not deemed to be a factor that
would preclude patients from choosing a
long-acting bronchodilator with ICS over a
long-acting bronchodilator therapy without
ICS. After considering these issues, the panel
did not suggest ICS as an additive therapy to
long-acting bronchodilators in patients with
COPD and blood eosinophilia, except for
those patients with a history of one or more
exacerbations in the past year.
Research needs. Well-designed clinical
trials with large sample sizes should be
conducted in patients with COPD and blood
eosinophilia. These studies should stratify
patients by eosinophil levels and
exacerbation risk. It is unclear whether
different threshold values for blood
eosinophilia would affect outcomes, and we
recommend further research to define the
most predictive threshold values. Finally,
research is needed to determine the
relevance of measuring changes in blood
eosinophil counts as a dynamic parameter,
and whether this may correlate with
treatment response (41).
Question 5: In Patients with COPD
Who Have a History of Severe and
Frequent Exacerbations despite
Otherwise Optimal Therapy, Is
Maintenance Oral Steroid Therapy
More Effective than and as Safe as No
Maintenance Oral Steroid Therapy?
Recommendation. In patients with COPD
and a history of severe and frequent
exacerbations despite otherwise optimal
therapy, we advise against the use of
maintenance oral corticosteroid therapy
(conditional recommendation, low certainty
evidence).
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Critical outcomes. Outcome
prioritization by the panel resulted in
ranking mortality, exacerbations, dyspnea,
hospital admissions, bone fractures, QOL,
and treatment-emergent adverse events as
critical outcomes.
Summary of the evidence. The expert
medical librarian initially identified 1,500
citations in MEDLINE (n= 777), Embase
(n= 664), and the Cochrane Library
(n= 59), with deduplication resulting in
n= 932 warranting abstract screening. The
majority (98.8%) were ineligible either
because of a nonrigorous study
methodology or lack of relevance to the
PICO question, resulting in the screeners
identifying 11 studies for final review
inclusion. Four of the 11 studies were RCTs
(42–45). The total sample size for the four
RCTs was 477 patients; 290 (60.8%)
of these patients were in the
treatment/intervention arms and 187
(39.2%) were in the control (comparator)
arms. The four studies were a combination
of single- and multicenter designs.
We initially analyzed both RCT and
observational (nonrandomized) evidence
for this question given the available
evidence, while recognizing that
nonrandomized evidence can be affected by
selection bias and residual confounding
(e.g., confounding by indication). After the
analysis, we judged the RCT evidence to be
the optimal evidence on which to base
this recommendation. As such, for the
application of GRADEmethods, we used the
RCT evidence in determining the certainty
of evidence, and we present the RCT
evidence for the respective patient-
important outcomes.
Mortality. Two studies (n= 241)
assessed mortality risk (42, 43). The studies
revealed no significant difference in
mortality with the use of oral steroid versus
no oral steroid (RR 1.01; 95% CI, 0.28–3.70;
P= 0.98). There was moderate certainty in
estimates of effect based on GRADE
(absolute risk effect was 0 fewer per 1,000
patients; 95% CI, 26 fewer to 98 more).
Exacerbations. Two studies (n= 108)
assessed exacerbation risk (43, 44). The
studies revealed no significant difference in
exacerbations with the use of maintenance
oral steroid versus no oral steroid (RR 1.38;
95% CI, 0.90–2.10; P= 0.14). There was
moderate certainty in estimates of effect
based on GRADE (absolute risk effect was
190 more per 1,000 patients; 95% CI, 50
fewer to 550 more).
Dyspnea (daily symptom score, visual
analog scale). Two studies (n= 142)
assessed dyspnea (43, 45). The studies
revealed no statistically significant
difference in dyspnea with the use of
maintenance oral steroids versus no oral
steroid (SMD=20.22; 95% CI, 20.56 to
0.12; P= 0.21). There was moderate
certainty in estimates of effect based on
GRADE (absolute risk effect was 0.22 SDs
lower; 95% CI, 0.56 lower to 0.12 higher).
Hospital admissions. One study
(n= 191) assessed the risk of hospital
admission (42). The study revealed no
significant difference in admissions with the
use of oral steroids versus no oral steroids
(RR, 0.64; 95% CI, 0.25–1.61; P= 0.34).
There was moderate certainty in estimates
of effect based on GRADE (absolute risk
effect was 42 fewer per 1,000 patients; 95%
CI, 88 fewer to 71 more).
Treatment-emergent adverse
events. Two studies (n= 247) assessed the
risk of treatment-emergent adverse events
(42, 43). The list of adverse events included
(but was not limited to) hyperglycemia,
hypertension, secondary infection, upper
gastrointestinal bleeding, acute psychiatric
illness requiring a consultation, an invasive
procedure, or initiation of a specific
therapy. The studies revealed a statistically
significant increased risk of adverse events
with oral steroid use versus no oral steroid
(RR, 1.65; 95% CI, 1.16–2.34; P= 0.006).
There was low certainty in estimates of
effect based on GRADE (absolute risk effect
was 174 more per 1,000 patients; 95% CI,
43 more to 359 more).
Summary. Based on the five critical
outcomes using RCT evidence and completion
of the GRADE evidence table, the overall
certainty of evidence was judged to be “low”
and this certainty was assigned to the final
recommendation as per GRADE guidance.
Committee discussion. The panel
believed that maintenance oral steroid
therapy has not been shown in clinical trials
to improve clinical outcomes, and the
available evidence suggests that chronic oral
steroid therapy has a potential for harm.
Two RCTs revealed an increased risk of
adverse events with oral steroid use,
suggesting excess adverse events (harms) in
patients who are prescribed daily oral
steroids. However, this recommendation
was based on RCTs that had small sample
sizes, a small number of events, short
durations, and broad CIs around the point
estimates. In addition, these studies
occurred when there was a paucity of
medications available for maintenance
therapy. The quality of the underlying
evidence was poor, and therefore the panel
believed that a recommendation in favor of
maintenance oral steroid use would be
problematic given the concerns surrounding
patient safety. The panel also believed that
well-informed patients would place a greater
value on avoiding the potential harms of
adverse events and less value on the
uncertain benefits of decreased dyspnea and
hospital admissions.
After considering these issues and the low
certainty of the evidence, the panel concluded
that in patients with COPD and a history of
severe and frequent exacerbations, the balance
of benefits of maintenance oral steroid therapy
did not outweigh the risks when compared
with no steroid use. Given that the panel
recommended against the intervention, issues
related to feasibility, acceptability, and health
equity were not discussed.
Research needs. Additional well-
designed clinical trials with large sample sizes,
conducted in real-life situations, could provide
the needed robust evidence to determine
whether the benefits of maintenance oral
steroid therapy might outweigh its harms. In
the meantime, the use of maintenance oral
steroid therapy in COPD treatment could be
considered by clinicians and well-informed
patients, underscoring the need for shared
decision-making.
Question 6: In Patients with COPD
Who Experience Advanced
Refractory Dyspnea despite
Otherwise Optimal Therapy, Is
Opioid-based Therapy More Effective
than and as Safe as No Additional
Therapy?
Recommendation. In individuals with
COPD who experience advanced refractory
dyspnea despite otherwise optimal therapy,
we suggest that opioid-based therapy be
considered for dyspnea management within
a personalized shared decision-making
approach (conditional recommendation,
very low certainty evidence).
Critical outcomes. Outcome
prioritization by the panel resulted in
ranking emergency department visits,
dyspnea, exacerbations, health-related QOL,
falls/accidents, overdose, and exercise
capacity as critical outcomes.
Summary of the evidence. The expert
medical librarian initially identified 576
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citations in MEDLINE (n= 267), Embase
(n= 193), and the Cochrane Library
(n= 116), with deduplication resulting in
n= 370 warranting abstract screening.
The majority (96.2%) were ineligible
either because of a nonrigorous study
methodology or lack of relevance to the
PICO question, and this resulted in
screeners identifying 14 studies for final
review inclusion. All of the 14 identified
studies were RCTs, and 13 of these studies
used a crossover design (46–59). Each RCT
had a relatively small sample size and the
total sample size for the 14 studies was 366
participants. There were 184 participants in
the treatment/intervention arms (opioid-
based treatment) across the trials (50.2%)
and 182 (49.7%) in the control
(comparator) arms. The majority of the 14
studies were single-center studies.
Exacerbations. One study (n= 30)
assessed exacerbation risk (53). The study
revealed no significant difference in
exacerbations between the opioid and
nonopioid groups (RR, 1.38; 95% CI,
0.74–2.55; P= 0.31). There was low
certainty in estimates of effect based on
GRADE (absolute risk effect was 190 more
exacerbations per 1,000 patients; 95% CI,
130 fewer to 775 more).
Emergency department visits. One
study (n=30) assessed the risk of emergency
department visits (53). However, the small
number of events and small sample size, as
well as zero events in one arm, resulted in an
excessively wide 95% CI, with unstable
estimates of effect. The study revealed no
significant difference in risk between the
opioid and nonopioid groups (RR, 4.41; 95%
CI, 0.23–84.79; P=0.33). There was low
certainty in estimates of effect based
on GRADE (absolute risk effect was 125
more admissions per 1,000 patients; 95% CI,
66 fewer to 316 more per 1,000 patients).
Falls/accidents. One study (n= 38) with
a small sample size assessed the risk of
falls/accidents (47). The evidence from this
study is very limited and underpowered. The
study revealed no significant difference in
risk of falls between the opioid and
nonopioid groups (RR, 0.37; 95% CI,
0.02–8.51; P=0.53). There was low certainty
in estimates of effect based on GRADE
(absolute risk effect was 32 fewer per 1,000
patients; 95% CI, 49 fewer to 376 more).
Overdose. One study (n=38) assessed
the risk of overdose/oversedation (47). The
study revealed no significant difference in risk
between the opioid and nonopioid groups
(RR, 3.32; 95% CI, 0.14–76.6; P=0.45). There
was low certainty in estimates of effect based
on GRADE (absolute risk effect was 56
more per 1,000 patients; 95% CI, 82 fewer
overdoses per 1,000 patients to 193 more per
1,000 patients).
Health-related QOL: assessed using a
visual analog scale. One study (n=40)
assessed health-related QOL (54). The study
revealed a significant difference in the visual
analog scale, with an increased score in the
group that was randomized to opioids
(MD=1.50; 95% CI, 0.66–2.34; P=0.03),
indicating improved QOL. There was very
low certainty in estimates of effect based on
GRADE (absolute risk effect was 1.50 fewer;
95% CI, 2.34 more to 0.66 more fewer).
Dyspnea: assessed using a variety of
methods, including diary cards, visual
analog scales, Medical Research Council
scale, and Chronic Respiratory Disease
Questionnaire dyspnea subscale. Twelve
studies (n= 240) assessed dyspnea (46, 47,
49–54, 56–59). The studies revealed a
significant difference in dyspnea, favoring
the group that received opioids
(SMD=20.60; 95% CI, 21.08 to 20.13;
P= 0.01), and this exceeded the MCID
threshold. There was low certainty in
estimates of effect based on GRADE
(absolute difference was 0.60 SDs lower;
95% CI, 1.08 lower to 0.13 lower). No
subgroup differences were noted when
systemic versus nebulized administration
subgroups were analyzed (P= 0.08).
Exercise capacity. Nine studies
(n= 103) assessed exercise capacity
(46, 48, 49, 51–56, 58). The data were pooled
across distance in meters, duration in
minutes, and workload capacity in watts.
The studies revealed no significant difference
between the opioid and no-opioid groups
(SMD=0.14; 95% CI, 21.42 to 1.70;
P= 0.86), and this did not reach the MCID
threshold. There was moderate certainty in
estimates of effect based on GRADE
(absolute difference was 0.14 SDs higher;
95% CI, 1.42 lower to 1.70 higher). No
subgroup differences were noted when
systemic versus nebulized administration
subgroups were analyzed (P=0.10).
Summary. Based on the eight critical
outcomes and completion of the GRADE
evidence table, the overall certainty
of evidence was judged to be “very low”
and this certainty was assigned to the final
recommendation as per GRADE guidance.
Committee discussion. The panel noted
that in patients with advanced refractory
dyspnea, there was a statistically and
clinically meaningful improvement in
dyspnea with opioid treatment. The panel
believed that a conditional recommendation
in favor of opioid use was reasonable for
dyspnea management given the
accumulated evidence, and that well-
informed patients might place a higher value
on the improvement in dyspnea and
less value on the uncertain harms of
exacerbations, hospitalizations, falls, or
overdoses. The panel believed that the
observed benefit in dyspnea outweighed the
uncertain risks. However, many of these
studies were undertaken when there
was a relative paucity of maintenance
medications available to treat COPD,
and the presumed effects of opioids
might differ in today’s clinical context.
Therefore, given the very low certainty
of evidence, the use of opioids must
be evaluated by clinicians and patients
in a shared decision-making process.
The panel debated the issues of
feasibility, acceptability, and health equity,
and felt confident that a trial of opioid
therapy to determine if there was individual
benefit could be implemented, would be
acceptable to patients, and would pose
limited (if any) health-equity challenges.
A cost-effectiveness analysis was not
performed, and the literature evidence
was not fully examined in this regard.
However, the panel also believed that opioid
treatment would not be prohibitively
expensive in terms of access to treatment.
The burden of use for patients was also not
deemed to be a factor that would preclude
patients from taking opioids for advanced
refractory dyspnea despite otherwise optimal
COPD therapy if prescribed. After
considering these issues, and armed with
very low certainty evidence, the panel
concluded that in individuals with COPD
who experience advanced refractory
dyspnea despite otherwise optimal therapy,
the balance of benefits of opioid therapy
may outweigh the risks when compared
with no opioid use. The panel suggested
that the use of opioid treatment in
COPD should be carefully considered by
both the clinician and the well-informed
patient, underscoring the need for shared
decision-making.
Research needs. Adequately powered,
well-designed studies with larger sample
sizes should be conducted in real-life
situations, which could provide needed
robust evidence. These studies could also
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allow for the inclusion of patients.80 years
of age and those with multiple comorbidities
in conjunction with opioid treatment.
Conclusions
In developing this guideline, we performed
a rigorous, PICO-driven distillation
of the scientific evidence to provide
recommendations pertaining to key
questions regarding the pharmacologic
treatment of COPD. We hope that
clinicians and researchers will find this
guideline useful; however, it is important
to apply these recommendations along
with clinical assessments and shared
decision-making to ensure that patients
receive optimal clinical care. We also
recognize that slowing the progression of
disease and improving mortality are
important goals of therapy; however,
pharmacotherapy has not definitely
been proven to affect these outcomes.
Improvements in COPD mortality
and disease progression have thus far
only been achieved through smoking
cessation.
The panel recognizes that there
are limitations to this clinical practice
guideline. The recommendations were
based on the available scientific evidence.
In many cases, the available clinical
trials did not include certain COPD
populations, such as patients over 80 years
of age, those with chronic comorbid
conditions, and those with COPD/asthma
overlap. In addition, the available
evidence did not risk stratify patients
with exacerbations or those with
eosinophilia. It is also important to note
that the panel did not include patient
representatives or family/caregiver
representatives. Their participation might
have been important in prioritizing clinical
outcomes.
Many questions remain regarding
the optimal pharmacologic therapy for
patients with varying risks of exacerbations
and varying levels of eosinophilia, as
well as potentially different responses
to medication among current and
former smokers. We hope that the
research priorities outlined in this
document will prompt new research to
identify more specific patient profiles and
enable personalized, patient-centered
care. n
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